Mark Farrah Associates Assessed Year-Over-Year Medicare Advantage and PDP Market Penetration and Performance
MCMURRAY, Pa.--(BUSINESS WIRE)--Mark Farrah Associates (MFA), www.markfarrah.com, assessed Medicare Advantage (MA), including Medicare Advantage with Prescription Drug Plan (MA-PD) and Prescription Drug Plan (PDP) performance, market share and market penetration by state as of March 1, 2025. Total MA membership stood at 34,601,557 and Medicare stand-alone PDPs covered 23,194,849 members.
Key highlights include:
The top ten carriers cover 78.8% of all MA enrollees, with UnitedHealth remaining the market share leader with over 9.9 million enrolled.
California experienced the most sizeable year-over-year increase, gaining over 123,000 members.
Stand-alone PDPs experienced a notable increase of approximately 398,000 members between March 2024 and March 2025.
Centene, CVS, UnitedHealth, Cigna, and Humana were the top five companies that currently dominate 89.5% of the PDP market.
Many companies conduct their post-OEP (Open Enrollment Period) competitive assessments by using tools such as Mark Farrah Associates' (MFA) Medicare Business Online™ and Health Coverage Portal™ to evaluate any changes in their market standings.
To read the FREE full text of ' Growth Rate for Medicare Advantage Plans Slowed in 2025", visit the Analysis Briefs library on Mark Farrah Associates' website.
Mark Farrah Associates (MFA) is a leading data aggregator and publisher providing health plan market data and analysis tools for the healthcare industry. MFA's Medicare Business Online™ (MBO) product simplifies the tracking of monthly Medicare Advantage and PDP enrollment by competitor. The Medicare Benefits Analyzer™ presents benefit copay comparisons across hundreds of benefit attributes by plan as reported in the Plan Finder on Medicare.gov. MFA also offers Med Supp market data enrollment and financial insights for companies interested in Medicare Supplement business. Committed to simplifying analysis of health insurance business, our products also include: Health Coverage Portal™, County Health Coverage™, Health Plans USA™ and 5500 Employer Health Plus. Follow us on LinkedIn!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
FDA Approved Anticancer Peptide Drug Conjugate Market Clinical Trials Insight
Global Peptide Drug Conjugate Market USD 1400 Million Opportunity Says Kuick Research In New Study Delhi, June 05, 2025 (GLOBE NEWSWIRE) -- Global Peptide Drug Conjugate Market, Drug Sales, Price, Dosage and Clinical Trials Insight 2030 Report Highlights: Global Peptide Drug Conjugate Market Opportunity: > USD 1400 Million Global Peptide Drug Conjugate Market Trends By Region and Indications Global Peptide Drug Conjugate Market Growth 2018-2024: > 300% Absolute Growth and 27% CAGR Growth Approved Peptide Drug Conjugate Dosage, Sales and Price Insight Approved Peptide Drug Conjugate Sales Global and Regional Insight: 2 Drugs Approved Global Peptide Drug Conjugate Clinical Trials Insight: > 30 Drugs Global Peptide Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase Peptide Drug Conjugate Proprietary Technologies and Methodologies Insight By Company Download Report: Peptide drug conjugates constitute a novel category of targeted therapies that make use of disease-targeting peptides to specifically deliver small molecule drugs to the target cells. This blended strategy enables drugs to be targeted more precisely to ailing tissues, minimizing systemic toxicity and maximizing therapeutic benefit. With more than 30 peptide drug conjugates candidates now in different stages of clinical trials, the domain is accelerating at breakneck speed. Most of these candidates are being developed and evaluated for oncology, where the demand for highly targeted therapies is still paramount. Nonetheless, investigations have also been pushed into neurodegenerative disease and inflammatory disorders, which suggests a wider therapeutic scope for this modality. As of May 2025, 2 peptide drug conjugates have been approved by the regulators. Novartis's Lutathera, a radiolabeled peptide for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), exemplifies the potential of targeted delivery in cancer. The second agent that has been approved, Pepaxti (melflufen), by Oncopeptides, is employed to treat multiple myeloma and demonstrates the utility of peptide to enhance the therapeutic index of known cytotoxic agents. All these achievements underscore the potential for peptide drug conjugates and have opened up doors for more firms to enter the pipeline for developing new candidates. Platform technologies are leading the way in driving peptide drug conjugate innovation. For example, PeptiDream's PDPS (Peptide Discovery Platform System) leverages massive libraries of macrocyclic peptides to quickly find high-affinity binders. They are optimized as targeting agents in peptide drug conjugates, enabling more targeted drug delivery. By targeting cytotoxic payloads directly to disease-associated receptors, these technologies reduce off-target effects, improving efficacy and safety for patients. The growing use of such platforms by biotech companies and pharmaceutical companies highlights their significance in the present drug development scenario. Regulatory assistance is also supporting the development of peptide drug conjugates. Sudocetaxel zendusortide (TH1902), a peptide drug conjugate from Theratechnologies, was granted the Fast Track Designation by the FDA. This candidate has been designed against sortilin-expressing solid tumors and is undergoing Phase 1 clinical trials. As the first compound from Theratechnologies' SORT1+ Technology™, it is an example of innovation in peptide targeting and an accelerated regulatory pathway that allows for accelerated development. Designations such as these not only support the therapeutic potential of these compounds but also foster investment and accelerate clinical advancement. The peptide drug conjugate field involves a diverse range of stakeholders, including major pharmaceutical companies like Novartis and Oncopeptides, as well as specialized biotechnology firms such as Bicycle Therapeutics and Theratechnologies. Additionally, contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) are increasingly becoming integral to the development process, providing essential services from early-stage discovery through to clinical and commercial manufacturing. In spite of this momentum, market hurdles exist. One major hindrance is the complexity of peptide drug conjugate manufacturing, which sometimes necessitates specialized facilities and intense quality control, potentially pushing up development expense. To overcome it, strategic alliances with seasoned CDMOs can streamline manufacturing and lower operational costs. Regulatory complexity regarding newer payloads or novel peptide-linker chemistries is another hurdle. Anticipation of the regulatory agencies through proactive interaction and utilization of existing designations can smooth over the complexity. Looking to the future, the prospects for peptide-drug conjugates are encouraging. As ever improving technology platforms advance and additional clinical information becomes available, peptide drug conjugates are destined to become a staple of targeted therapy, not just oncology, but perhaps a wide variety of chronic and orphan diseases. CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@ +91-470679900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
40 minutes ago
- Business Wire
Blue Cross of Idaho Partners with Greater Good Health to Enable Value-Based Care Delivery for Members
MERIDIAN, Idaho & EL SEGUNDO, Calif.--(BUSINESS WIRE)--Blue Cross of Idaho and Greater Good Health announced a strategic partnership that will improve access to high-quality, value-based care for Blue Cross of Idaho's Medicare Advantage members. Granite Financial Holdings, LLC, the investment affiliate of Blue Cross of Idaho, is investing in Greater Good Health to fund the development of senior-focused primary care clinics and other clinical services to drive improved health outcomes for Blue Cross of Idaho's Medicare Advantage members. 'We are proud to partner with Blue Cross to offer seniors the high-quality, value-based care they deserve.' Sylvia Hastanan, Founder and CEO of Greater Good Health 'Blue Cross of Idaho is driven to find the right care at the right time for our members, especially for seniors on our Medicare Advantage plans,' said Drew Hobby, Chief Strategy Officer for Blue Cross of Idaho. 'Greater Good Health has a strong emphasis on tailoring a healthcare experience to the unique needs of seniors, such as unhurried appointments, convenience and a whole-person approach to care. These factors, combined with their collaboration with provider groups, have delivered strong health-outcomes and high patient satisfaction scores. We're excited about our new partnership for our members in Bonneville and Jefferson counties.' Greater Good Health delivers clinical programs designed to advance value-based care, enhance the capacity of healthcare organizations to serve vulnerable populations, and expand patient access to care. Central to all of Greater Good Health clinical programs is a committment to improving clinical outcomes and delivering an exceptional patient experience. 'Nationwide shortages of primary care physicians have created significant barriers to accessing care, a challenge that is even more pronounced in regions like Idaho, where seniors may wait months for a primary care appointment,' said Sylvia Hastanan, founder and CEO of Greater Good Health. 'We are proud to partner with Blue Cross to offer seniors the high-quality, value-based care they deserve.' Greater Good Health and Blue Cross of Idaho are planning to have their first senior-focused primary care clinic open in Idaho Falls, Idaho later this year with additional future locations to be determined. About Greater Good Health Greater Good Health is a healthcare organization enabling and expanding access to value-based care. Through an innovative Nurse Practitioner-centric model, Greater Good Health partners with health plans to build primary care practices in underserved communities, and partners with risk-bearing organizations to deploy private-labeled clinical programs that enable the shift to value-based, outcomes-focused care. Greater Good Health's proven care model and clinical programs benefit patients, providers, and payers alike, improving outcomes, reducing costs, and delivering a best-in-class patient experience. About Granite Financial Holdings Granite Financial Holdings, LLC is the investment affiliate of Blue Cross of Idaho Health Service, Inc. and a subsidiary of Gemstone Holdings, Inc. an Idaho-based, non-profit mutual insurance holding company dedicated to improving the health of the communities we serve by working to improve access to care, lower the cost of care and by offering innovative solutions to help individuals live healthier lives. About Blue Cross of Idaho Blue Cross of Idaho is the State of Idaho's oldest and largest health insurer, and the only Idaho-based insurer serving the entire state. Blue Cross of Idaho has a broad portfolio of health plans for employers of all sizes, as well as individual and Medicare plans offering innovative solutions to meet the unique needs of Idahoans and Idaho-based employers. Blue Cross of Idaho Health Service, Inc. is an affiliate of Granite Financial Holdings, LLC and a subsidiary of Gemstone Holdings, Inc.
The Hill
2 hours ago
- The Hill
Medicare changes on table for big, beautiful bill, says GOP senator
Sen. Thom Tillis (R-N.C.), a member of the Senate Finance Committee, on Thursday said GOP lawmakers are looking at changes to Medicare to root out waste, fraud and abuse. Republican senators are taking a closer look at finding savings in Medicare to increase the total amount of deficit reduction in President Trump's 'big, beautiful bill,' Tillis said a day after the Finance panel met with Trump at the White House. The Congressional Budget Office released a report this week estimating that the House-passed 1,116-page bill would add $2.4 trillion to the national debt over the next decade. Tillis says that overhauling systems at the Centers for Medicare & Medicaid Services (CMS) could save a substantial amount of money without impacting Medicare benefits, which Trump has said should not be cut. He said that legislation sponsored by Sens. Bill Cassidy (R-N.C.) and Jeff Merkley (D-Ore.) to reduce Medicare Advantage overpayments could be included into the bigger bill. 'Waste, fraud and abuse, you've got upcoding,' Tillis said. 'Even in the plumbing of CMS — and by that I mean, procurement, matching up contracts, duplicate payments — there are a number of things that I think that we could find that never touch a beneficiary of Medicare or Medicaid that we're going to go after.' Tillis said there are 'a number' of things that could be reformed under CMS's jurisdiction. 'In the plumbing of CMS, if you take look at contracting, contract execution, contract compliance, duplicate payments, there are a number of things that haven't been touched by the prior administration,' he said. He said that Cassidy has 'a very well thought out plan' to root out waste in Medicare Advantage. 'Bill is a physician, wants to make sure that we're maintaining quality care and I think he's done a very, very good job of highlighting the opportunity for hundreds of billions of dollars in savings,' he added. Tillis said 'you could do those provisions' in the big, beautiful bill, which Senate Republicans are trying to get to Trump's desk by July 4. 'It's basically CMS modernization,' he said.
